BLAINJECTIONINJECTABLE
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
SAIZEN (somatropin) by Emergent BioSolutions is cells. Approved for growth hormone deficiency, turner syndrome, small for gestational age. First approved in 1996.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAIZEN (somatropin) is a recombinant human growth hormone administered by injection that treats growth hormone deficiency and related growth disorders across pediatric and adult populations. The drug works by binding to growth hormone receptors on target cells, triggering intracellular signaling that induces IGF-1 production and stimulates protein synthesis, chondrocyte proliferation, and skeletal growth. It is indicated for 23 conditions including Turner syndrome, chronic kidney disease, idiopathic short stature, and growth retardation from various etiologies.
$0.122BPart D
LOE ApproachingSAIZEN is approaching loss of exclusivity with minimal Part D penetration ($122K, 35 claims in 2023), indicating a niche or declining brand requiring defensive commercial strategies and potential portfolio repositioning.
Mechanism of Action
cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or effects mediated indirectly by IGF-1,…
Indications (3)
Worked on SAIZEN at Emergent BioSolutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.